194 related articles for article (PubMed ID: 26462516)
1. [Escape mechanisms to the innate immune response in HPV-associated cervical cancer].
del Toro-Arreola S; García-Chagollán M; Jave-Suárez LF
Rev Med Inst Mex Seguro Soc; 2015; 53 Suppl 2():S194-9. PubMed ID: 26462516
[TBL] [Abstract][Full Text] [Related]
2. [Immune response in cervical cancer. Strategies for the development of therapeutic vaccines].
Mora-García ML; Monroy-García A
Rev Med Inst Mex Seguro Soc; 2015; 53 Suppl 2():S206-11. PubMed ID: 26462518
[TBL] [Abstract][Full Text] [Related]
3. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer.
Sasagawa T; Takagi H; Makinoda S
J Infect Chemother; 2012 Dec; 18(6):807-15. PubMed ID: 23117294
[TBL] [Abstract][Full Text] [Related]
4. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy.
Bhat P; Mattarollo SR; Gosmann C; Frazer IH; Leggatt GR
Immunol Rev; 2011 Jan; 239(1):85-98. PubMed ID: 21198666
[TBL] [Abstract][Full Text] [Related]
5. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
[TBL] [Abstract][Full Text] [Related]
6. Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical neoplasia in the lower female genital tract: a review.
Tjiong MY; Out TA; Ter Schegget J; Burger MP; Van Der Vange N
Int J Gynecol Cancer; 2001; 11(1):9-17. PubMed ID: 11285028
[TBL] [Abstract][Full Text] [Related]
7. Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape.
Conesa-Zamora P
Gynecol Oncol; 2013 Nov; 131(2):480-8. PubMed ID: 23994536
[TBL] [Abstract][Full Text] [Related]
8. Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia.
Sheu BC; Chang WC; Lin HH; Chow SN; Huang SC
J Obstet Gynaecol Res; 2007 Apr; 33(2):103-13. PubMed ID: 17441881
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms used by human papillomaviruses to escape the host immune response.
Kanodia S; Fahey LM; Kast WM
Curr Cancer Drug Targets; 2007 Feb; 7(1):79-89. PubMed ID: 17305480
[TBL] [Abstract][Full Text] [Related]
10. Chapter 5: Viral and host factors in human papillomavirus persistence and progression.
Wang SS; Hildesheim A
J Natl Cancer Inst Monogr; 2003; (31):35-40. PubMed ID: 12807943
[TBL] [Abstract][Full Text] [Related]
11. APOBEC-mediated genomic alterations link immunity and viral infection during human papillomavirus-driven cervical carcinogenesis.
Chen L; Qiu X; Zhang N; Wang Y; Wang M; Li D; Wang L; Du Y
Biosci Trends; 2017 Sep; 11(4):383-388. PubMed ID: 28717061
[TBL] [Abstract][Full Text] [Related]
12. Origin and immunoescape of uterine cervical cancer.
Van Hede D; Langers I; Delvenne P; Jacobs N
Presse Med; 2014 Dec; 43(12 Pt 2):e413-21. PubMed ID: 25448124
[TBL] [Abstract][Full Text] [Related]
13. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
[TBL] [Abstract][Full Text] [Related]
14. Why Human Papillomavirus Acute Infections Matter.
Alizon S; Murall CL; Bravo IG
Viruses; 2017 Oct; 9(10):. PubMed ID: 28994707
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of human papillomavirus genotyping.
Choi YJ; Park JS
J Gynecol Oncol; 2016 Mar; 27(2):e21. PubMed ID: 26768784
[TBL] [Abstract][Full Text] [Related]
16. Prevention of human papilloma virus-induced preneoplasia and cancer by prophylactic HPV vaccines.
Hampl M
Minerva Med; 2007 Apr; 98(2):121-30. PubMed ID: 17519854
[TBL] [Abstract][Full Text] [Related]
17. Strategies for the prevention of cervical cancer by human papillomavirus vaccination.
Williamson AL; Passmore JA; Rybicki EP
Best Pract Res Clin Obstet Gynaecol; 2005 Aug; 19(4):531-44. PubMed ID: 16150392
[TBL] [Abstract][Full Text] [Related]
18. HPV variants and HLA polymorphisms: the role of variability on the risk of cervical cancer.
de Araujo Souza PS; Sichero L; Maciag PC
Future Oncol; 2009 Apr; 5(3):359-70. PubMed ID: 19374542
[TBL] [Abstract][Full Text] [Related]
19. Innate immunity and HPV: friends or foes.
Nunes RAL; Morale MG; Silva GÁF; Villa LL; Termini L
Clinics (Sao Paulo); 2018 Oct; 73(suppl 1):e549s. PubMed ID: 30328949
[TBL] [Abstract][Full Text] [Related]
20. Role of IL-10 in immune suppression in cervical cancer.
Bhairavabhotla RK; Verm V; Tongaonkar H; Shastri S; Dinshaw K; Chiplunkar S
Indian J Biochem Biophys; 2007 Oct; 44(5):350-6. PubMed ID: 18341210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
